Drugs / wSp vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07059182 | Jun → Aug 2025 | idiopathic severe pneumococcemia, otitis media | Serum Life Science Europe GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07216430 | Sep 2025 → Jun 2028 expected | otitis media | Serum Life Science Europe GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | wSp vaccine | “Single intramuscular injection of 1 mg protein/0.5 mL wSp vaccine” NCT07059182 ↗ |
| Modality | Vaccine | “whole-cell Streptococcus pneumoniae (wSp) vaccination” NCT07059182 ↗ |
| Route | Intramuscular | “0.5 mL of study product will be administered in the participant's deltoid as an intramuscular injection” NCT07059182 ↗ |